<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02327000</url>
  </required_header>
  <id_info>
    <org_study_id>GLA5PR-104</org_study_id>
    <nct_id>NCT02327000</nct_id>
  </id_info>
  <brief_title>A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GL Pharm Tech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GL Pharm Tech Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to compare the pharmacokinetic characteristics of
      GLA5PR GLARS tablet 150mg and Lyrica Capsule 75mg.

      GLA5PR GLARS tablet 150mg is a New Formulation which is made by GL Pharm Tech.

      GLARS(Geometrically Long Absorption Regulated System) is New Solution to Sustained Absorption
      by Extending the Absorption Site.

      To overcome the shortcomings of the currently existing sustained release drug delivery
      technologies the investigators have recently developed a novel drug delivery system to enable
      a drug to be dissolved irrespective of the surrounding environment and further absorbed up to
      colon. The investigators coined this &quot;Geometrically Long Absorption Regulated System(GLARS)&quot;.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Basically, this system is a triple-layered tablet, comprised of upper and lower layers that
      swell and draw a sufficient amount of water, plus a highly water - soluble middle layer that
      rapidly draw water into the tablet core simultaneously.

      The water drawn into the tablet (about 3 to 4 times the weight of the tablet itself)
      functions as an additional media which enables additional and later drug release out of the
      dosage form. This serves to overcome the shortage of surrounding media that has been reported
      to be one of the key reasons for mal-absorption of a drug in colon.

      As the middle layer induces a rapid water draw into the tablet core, the penetrated water
      also diffuses to the upper and lower layers, which makes the tablet to rapidly swell and
      controls drug release.

      At virtually the same time, the swollen upper and lower layers form to surround a lateral
      side of the middle layer, which can, in turn, further control drug release.

      This relatively rigid swollen matrix structure makes drug release not affected by surrounding
      mechanical flux, which can provide relatively consistent in vivo drug release irrespective of
      degree of gastrointestinal motility.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>36hrs</time_frame>
    <description>Pharmacokinetic of Pregabalin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>36hrs</time_frame>
    <description>Pharmacokinetic of Pregabalin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>36hrs</time_frame>
    <description>Pharmacokinetic of Pregabalin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>36hrs</time_frame>
    <description>Pharmacokinetic of Pregabalin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>36hrs</time_frame>
    <description>Pharmacokinetic of Pregabalin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>36hrs</time_frame>
    <description>Pharmacokinetic of Pregabalin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>36hrs</time_frame>
    <description>Pharmacokinetic of Pregabalin</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLA5PR GLARS-NF1 tablet 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day, after meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLA5PR GLARS-NF1 tablet 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day, after meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLA5PR GLARS-NF1 tablet 450mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLA5PR GLARS-NF1 tablet 450mg/day(Pregabalin 150mg 1 tablet and Pregabalin 300mg 1 tablet, 1 times a day, after meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLA5PR GLARS-NF1 tablet 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLA5PR GLARS-NF1 tablet 600mg/day(Pregabalin 300mg, 2 tablets 1 times a day, after meal)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 150mg</intervention_name>
    <description>GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)</description>
    <arm_group_label>GLA5PR GLARS-NF1 tablet 150mg</arm_group_label>
    <arm_group_label>GLA5PR GLARS-NF1 tablet 450mg</arm_group_label>
    <other_name>GLA5PR GLARS-NF1 tablet 150mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 300mg</intervention_name>
    <description>GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)</description>
    <arm_group_label>GLA5PR GLARS-NF1 tablet 300mg</arm_group_label>
    <arm_group_label>GLA5PR GLARS-NF1 tablet 450mg</arm_group_label>
    <arm_group_label>GLA5PR GLARS-NF1 tablet 600mg</arm_group_label>
    <other_name>GLA5PR GLARS-NF1 tablet 300mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19~45 years old, Healthy Adult Male Subject

          -  17.5~30.5kg/m2(BMI) and ≥ 40kg(Body Weight)

        Exclusion Criteria:

          -  SBP ≥ 140mmHg or DBP ≥ 90mmHg
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2014</study_first_submitted>
  <study_first_submitted_qc>December 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2014</study_first_posted>
  <last_update_submitted>December 23, 2014</last_update_submitted>
  <last_update_submitted_qc>December 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

